Mitral Disease Patients

Mitral valve disease is one of the most common yet dangerously undertreated heart conditions, affecting millions worldwide. The mitral valve controls blood flow between the upper and lower chambers on the left side of your heart. When it malfunctions by leaking backward (regurgitation) or becoming narrowed (stenosis), the consequences can be devastating. Globally, about 24 million people suffer from degenerative mitral valve disease, with prevalence exceeding 10% in those over age 75.

Despite its frequency, mitral disease carries a grim prognosis when left untreated: studies show that 90% of patients with severe mitral regurgitation are either dead or require surgery within 10 years, with heart failure developing in 64% of patients within just 5 years of diagnosis. Patients with mitral disease face more than double the mortality risk compared to healthy individuals of the same age, with sudden death accounting for one-quarter of these fatalities.

Despite these outcomes, only 15% of affected patients receive potentially life-saving mitral valve surgery, even in communities with full access to advanced cardiac care. This treatment gap is a massive unmet medical need. Early surgical intervention has been proven to improve outcomes, reducing cardiovascular death by 82% and heart failure by 71% compared to watchful waiting. The burden extends beyond individual suffering to society, with disability-adjusted life-years rising as populations age.

 Mythralica addresses this critical unmet need through disciplined engineering and evidence-based design. It combines physiological relevance with a pragmatic, cost-efficient development pathway to make effective mitral valve treatment accessible to the millions who need it.